62 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Arena Pharmaceuticals
Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT
Arena Pharmaceuticals
Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
Arena Pharmaceuticals
Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat.
Arena Pharmaceuticals
Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor.
Arena Pharmaceuticals
Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
Arena Pharmaceuticals
(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.
Arena Pharmaceuticals
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
Arena Pharmaceuticals
Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.
Arena Pharmaceuticals
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Arena Pharmaceuticals
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.
Arena Pharmaceuticals
Fused tricyclic indoles as S1P1 agonists with robust efficacy in animal models of autoimmune disease.
Arena Pharmaceuticals
Nicotinic acid receptor agonists differentially activate downstream effectors.
Arena Pharmaceuticals
A new family of H3 receptor antagonists based on the natural product Conessine.
Arena Pharmaceuticals
Identification of fused bicyclic heterocycles as potent and selective 5-HT(2A) receptor antagonists for the treatment of insomnia.
Arena Pharmaceuticals
Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Arena Pharmaceuticals
Identification of biaryl sulfone derivatives as antagonists of the histamine H3 receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).
Arena Pharmaceuticals
Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P¿? agonists.
Arena Pharmaceuticals
Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.
Arena Pharmaceuticals
Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.
Arena Pharmaceuticals
Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis.
Arena Pharmaceuticals
Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a).
Arena Pharmaceuticals
Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.
Arena Pharmaceuticals
Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
Arena Pharmaceuticals
Solubilized phenyl-pyrazole ureas as potent, selective 5-HT(2A) inverse-agonists and their application as antiplatelet agents.
Arena Pharmaceuticals
Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Arena Pharmaceuticals
5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b.
Arena Pharmaceuticals
Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Arena Pharmaceuticals
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.
Arena Pharmaceuticals
Novel H3 receptor antagonists with improved pharmacokinetic profiles.
Arena Pharmaceuticals
3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b.
Arena Pharmaceuticals
Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a.
Arena Pharmaceuticals
Agonist lead identification for the high affinity niacin receptor GPR109a.
Arena Pharmaceuticals
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
Arena Pharmaceuticals
Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.
Arena Pharmaceuticals
Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT
Arena Pharmaceuticals
Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Arena Pharmaceuticals
Discovery of APD371: Identification of a Highly Potent and Selective CB
Arena Pharmaceuticals
CYCLOPROPANECARBOXAMIDE-CONTAINING COMPOUNDS AND APPLICATION THEREOF
Cgenetech (Suzhou, China)
1,7-naphthyridine derivative and preparation method and use therefor
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
HDAC inhibitor compounds and methods of treatment
University of Florida Research Foundation
Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
Aurigene Discovery Technologies
Compounds that participate in cooperative binding and uses thereof
Revolution Medicines
Thiophene, manufacturing method thereof, and pharmaceutical application of same
Cstone Pharmaceutical (Suzhou)
Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Array Biopharma
Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
Takeda Pharmaceutical
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
Ondokuz Mayis University
Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors.
Riken Center For Life Science Technologies
Synthesis of 4-thiazolidinone analogs as potent in vitro anti-urease agents.
Hazara University
2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
Albany Molecular Research
Substituted quinolines and their use as medicaments
Boehringer Ingelheim International
Anti-infective agents against intracellular pathogens
The Ohio State University Research Foundation